Identification

Name
Tiaprofenic acid
Accession Number
DB01600
Type
Small Molecule
Groups
Approved
Description

Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain.

Structure
Thumb
Synonyms
  • 2-(5-Benzoyl-thiophen-2-yl)-propionic acid
  • 2-(5-Benzyl-2-thienyl)propionsaeure
  • 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid
  • 5-Benzoyl-alpha-methylthiophene-2-acetic acid
  • Acide tiaprofenique
  • Acido tiaprofenico
  • Acidum tiaprofenicum
  • alpha-Methyl-5-benzoyl-2-thienylacetic acid
  • Tiaprofensaeure
  • Tiaprofensäure
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert Tiafen SRCapsule, extended release300 mgOralAventis Pharma Ltd.Not applicableNot applicableCanada
Albert Tiafen Tab 200mgTablet200 mgOralAventis Pharma Ltd.1991-12-312004-07-30Canada
Albert Tiafen Tab 300mgTablet300 mgOralAventis Pharma Ltd.1991-12-312004-07-30Canada
SurgamTablet300 mgOralSanofi Aventis1997-08-202007-11-22Canada
Surgam SRCapsule, extended release300 mgOralSanofi Aventis1997-02-212007-07-31Canada
Surgam SR Cap 300mgCapsule, extended release300 mgOralHoechst Roussel Canada Inc.1990-12-311999-08-11Canada
Surgam Tab 200mgTablet200 mgOralRoussel Canada Inc.1986-12-311997-08-05Canada
Surgam Tab 200mgTablet200 mgOralHoechst Roussel Canada Inc.1996-12-312001-07-20Canada
Surgam Tab 300mgTablet300 mgOralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada
Surgam Tab 300mgTablet300 mgOralRoussel Canada Inc.1986-12-311997-08-05Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tiaprofenic Tablets -300mgTablet300 mgOralApotex Corporation1994-12-31Not applicableCanada
Apo-tiaprofenic Tablets-200mgTablet200 mgOralApotex Corporation1994-12-31Not applicableCanada
Dom-tiaprofenicTablet200 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-tiaprofenicTablet300 mgOralDominion Pharmacal2000-06-20Not applicableCanada
Nu-tiaprofenic - Tab 200mgTablet200 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-tiaprofenic - Tab 300mgTablet300 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Penta-tiaprofenic TabletsTablet200 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-tiaprofenic TabletsTablet300 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-tiaprofenicTablet300 mgOralPharmascience Inc1997-07-08Not applicableCanada
PMS-tiaprofenicTablet200 mgOralPharmascience Inc1999-01-24Not applicableCanada
International/Other Brands
Surgamyl
Categories
UNII
1LS1T6R34C
CAS number
33005-95-7
Weight
Average: 260.308
Monoisotopic: 260.05071494
Chemical Formula
C14H12O3S
InChI Key
GUHPRPJDBZHYCJ-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
IUPAC Name
2-(5-benzoylthiophen-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1

Pharmacology

Indication

Tiaprofenic acid is used to treat pain, especially arthritic pain.

Associated Conditions
Pharmacodynamics

Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.

Mechanism of action

Tiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Bioavailability is 90% following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.

Route of elimination
Not Available
Half life

1.5-2.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Tiaprofenic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tiaprofenic acid.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabTiaprofenic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTiaprofenic acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tiaprofenic acid.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Tiaprofenic acid.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tiaprofenic acid.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.Approved
AliskirenTiaprofenic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tiaprofenic acid.Experimental
AlprenololTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideTiaprofenic acid may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tiaprofenic acid.Approved
AncrodTiaprofenic acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tiaprofenic acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tiaprofenic acid.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.Approved, Investigational
Antithrombin III humanTiaprofenic acid may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Antrafenine.Approved
ApixabanTiaprofenic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Tiaprofenic acid.Investigational
ApramycinTiaprofenic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tiaprofenic acid.Approved, Investigational
ArbekacinTiaprofenic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTiaprofenic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTiaprofenic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineTiaprofenic acid may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Atamestane.Investigational
AtenololTiaprofenic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tiaprofenic acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tiaprofenic acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tiaprofenic acid.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tiaprofenic acid.Approved, Investigational
BazedoxifeneTiaprofenic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminTiaprofenic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Tiaprofenic acid.Approved, Investigational
BefunololTiaprofenic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTiaprofenic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Tiaprofenic acid.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Tiaprofenic acid.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tiaprofenic acid.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tiaprofenic acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Tiaprofenic acid.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tiaprofenic acid.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tiaprofenic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololTiaprofenic acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tiaprofenic acid.Approved, Investigational
BevantololTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Tiaprofenic acid.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
BisoprololTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTiaprofenic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tiaprofenic acid.Investigational
BucindololTiaprofenic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tiaprofenic acid.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Bufexamac.Approved, Experimental
BufuralolTiaprofenic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Tiaprofenic acid.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tiaprofenic acid.Approved
BupranololTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tiaprofenic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tiaprofenic acid.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiaprofenic acid.Approved, Vet Approved, Withdrawn
CarteololTiaprofenic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTiaprofenic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tiaprofenic acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiaprofenic acid.Approved, Investigational
CeliprololTiaprofenic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTiaprofenic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiaprofenic acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
ChlorotrianiseneTiaprofenic acid may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tiaprofenic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tiaprofenic acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cimicoxib.Investigational
CinoxacinTiaprofenic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinTiaprofenic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Tiaprofenic acid.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Tiaprofenic acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
CloranololTiaprofenic acid may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneTiaprofenic acid may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensTiaprofenic acid may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Tiaprofenic acid.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tiaprofenic acid.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinTiaprofenic acid may increase the thrombogenic activities of Daidzein.Experimental
DalteparinTiaprofenic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTiaprofenic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Tiaprofenic acid.Investigational
DarexabanTiaprofenic acid may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Delapril.Investigational
DesipramineTiaprofenic acid may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinTiaprofenic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tiaprofenic acid.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tiaprofenic acid.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Tiaprofenic acid.Experimental
DextranTiaprofenic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinTiaprofenic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tiaprofenic acid.Approved, Vet Approved
DicoumarolTiaprofenic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolTiaprofenic acid may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolTiaprofenic acid may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Tiaprofenic acid.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tiaprofenic acid.Approved
DihydrostreptomycinTiaprofenic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tiaprofenic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid.Approved
DiphenadioneTiaprofenic acid may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Tiaprofenic acid.Approved
DrospirenoneTiaprofenic acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Tiaprofenic acid.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tiaprofenic acid.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Tiaprofenic acid.Investigational
Edetic AcidTiaprofenic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTiaprofenic acid may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Enalaprilat.Approved
EnoxacinTiaprofenic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTiaprofenic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tiaprofenic acid.Experimental
EpanololTiaprofenic acid may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolTiaprofenic acid may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tiaprofenic acid.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tiaprofenic acid.Experimental
EplerenoneTiaprofenic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilin.Approved
EquolTiaprofenic acid may increase the thrombogenic activities of Equol.Investigational
EsatenololTiaprofenic acid may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
EsmololTiaprofenic acid may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateTiaprofenic acid may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateTiaprofenic acid may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateTiaprofenic acid may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolTiaprofenic acid may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedTiaprofenic acid may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Tiaprofenic acid.Experimental
Ethyl biscoumacetateTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tiaprofenic acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tiaprofenic acid.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Tiaprofenic acid.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Tiaprofenic acid.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tiaprofenic acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tiaprofenic acid.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tiaprofenic acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiaprofenic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tiaprofenic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Tiaprofenic acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Tiaprofenic acid.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Tiaprofenic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tiaprofenic acid.Approved, Investigational
FleroxacinTiaprofenic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tiaprofenic acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fludrocortisone.Approved, Investigational
FluindioneTiaprofenic acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTiaprofenic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Tiaprofenic acid.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Tiaprofenic acid.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Tiaprofenic acid.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiaprofenic acid.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Tiaprofenic acid.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tiaprofenic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxTiaprofenic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tiaprofenic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Fosinopril.Approved
FramycetinTiaprofenic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
GabexateTiaprofenic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTiaprofenic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tiaprofenic acid.Approved, Withdrawn
GemifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTiaprofenic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinTiaprofenic acid may increase the thrombogenic activities of Genistein.Investigational
GentamicinTiaprofenic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATiaprofenic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Tiaprofenic acid.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Tiaprofenic acid.Approved
GrepafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Tiaprofenic acid.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HE3286.Investigational
HeparinTiaprofenic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolTiaprofenic acid may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Tiaprofenic acid.Investigational
HydralazineTiaprofenic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Tiaprofenic acid.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Tiaprofenic acid.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Tiaprofenic acid.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
Hygromycin BTiaprofenic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tiaprofenic acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tiaprofenic acid.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icosapent.Approved, Nutraceutical
IdraparinuxTiaprofenic acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Tiaprofenic acid.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Tiaprofenic acid.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.Approved
IndenololTiaprofenic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Tiaprofenic acid.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tiaprofenic acid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.Approved, Investigational
IsepamicinTiaprofenic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tiaprofenic acid.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Istaroxime.Investigational
KanamycinTiaprofenic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tiaprofenic acid.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tiaprofenic acid.Approved
LabetalolTiaprofenic acid may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LandiololTiaprofenic acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tiaprofenic acid.Approved, Investigational
LepirudinTiaprofenic acid may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LetaxabanTiaprofenic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololTiaprofenic acid may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololTiaprofenic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tiaprofenic acid.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.Experimental
LomefloxacinTiaprofenic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Tiaprofenic acid.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Tiaprofenic acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tiaprofenic acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tiaprofenic acid.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tiaprofenic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiaprofenic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiaprofenic acid.Approved
MelagatranTiaprofenic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.Approved, Vet Approved
MepindololTiaprofenic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tiaprofenic acid.Approved
MestranolTiaprofenic acid may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tiaprofenic acid.Approved, Investigational, Withdrawn
MethallenestrilTiaprofenic acid may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tiaprofenic acid.Approved, Vet Approved
MetipranololTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.Approved
MetoprololTiaprofenic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Tiaprofenic acid.Investigational, Withdrawn
MicronomicinTiaprofenic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tiaprofenic acid.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tiaprofenic acid.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Tiaprofenic acid.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tiaprofenic acid.Approved
MoxestrolTiaprofenic acid may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tiaprofenic acid.Approved
NadololTiaprofenic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTiaprofenic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tiaprofenic acid.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tiaprofenic acid.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tiaprofenic acid.Investigational
Nalidixic AcidTiaprofenic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiaprofenic acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with NCX 1022.Investigational
NeamineTiaprofenic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTiaprofenic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Tiaprofenic acid.Approved, Withdrawn
NemonoxacinTiaprofenic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tiaprofenic acid.Approved, Investigational
NetilmicinTiaprofenic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Tiaprofenic acid.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Tiaprofenic acid.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tiaprofenic acid.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tiaprofenic acid.Investigational
NorfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tiaprofenic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiaprofenic acid.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Tiaprofenic acid.Vet Approved
OtamixabanTiaprofenic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.Approved
Oxolinic acidTiaprofenic acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiaprofenic acid.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tiaprofenic acid.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Tiaprofenic acid.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Tiaprofenic acid.Approved, Investigational
PazufloxacinTiaprofenic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTiaprofenic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTiaprofenic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTiaprofenic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Perindopril.Approved
PhenindioneTiaprofenic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTiaprofenic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiaprofenic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.Approved, Investigational
PindololTiaprofenic acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTiaprofenic acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tiaprofenic acid.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tiaprofenic acid.Approved, Investigational
Piromidic acidTiaprofenic acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Tiaprofenic acid.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTiaprofenic acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTiaprofenic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateTiaprofenic acid may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tiaprofenic acid.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pomalidomide.Approved
Porfimer sodiumTiaprofenic acid may increase the photosensitizing activities of Porfimer sodium.Approved, Investigational
Potassium CitrateTiaprofenic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololTiaprofenic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tiaprofenic acid.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Tiaprofenic acid.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tiaprofenic acid.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Tiaprofenic acid can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Tiaprofenic acid.Experimental
PromestrieneTiaprofenic acid may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tiaprofenic acid.Approved, Investigational
PropafenoneTiaprofenic acid may decrease the antihypertensive activities of Propafenone.Approved
PropranololTiaprofenic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Tiaprofenic acid.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Tiaprofenic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tiaprofenic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tiaprofenic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tiaprofenic acid.Vet Approved
Protein CTiaprofenic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanTiaprofenic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTiaprofenic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTiaprofenic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tiaprofenic acid.Investigational
PuromycinTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Quinapril.Approved, Investigational
QuinestrolTiaprofenic acid may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tiaprofenic acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinTiaprofenic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.Approved, Investigational
RivaroxabanTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tiaprofenic acid.Approved, Investigational, Withdrawn
RosoxacinTiaprofenic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTiaprofenic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tiaprofenic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tiaprofenic acid.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tiaprofenic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tiaprofenic acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tiaprofenic acid.Approved, Investigational
SecoisolariciresinolTiaprofenic acid may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Tiaprofenic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tiaprofenic acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tiaprofenic acid.Investigational
SertralineSertraline may increase the antiplatelet activities of Tiaprofenic acid.Approved
SisomicinTiaprofenic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Tiaprofenic acid.Approved
SotalolTiaprofenic acid may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinTiaprofenic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tiaprofenic acid.Investigational
StreptomycinTiaprofenic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiaprofenic acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiaprofenic acid.Approved, Investigational
SulodexideTiaprofenic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tiaprofenic acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Tiaprofenic acid.Experimental
Synthetic Conjugated Estrogens, ATiaprofenic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BTiaprofenic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusTiaprofenic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tiaprofenic acid.Approved
TalinololTiaprofenic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tiaprofenic acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tiaprofenic acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tiaprofenic acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.Approved, Investigational
TemafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Tiaprofenic acid.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiaprofenic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Tiaprofenic acid.Vet Approved
TerbutalineTiaprofenic acid may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tiaprofenic acid.Approved
TertatololTiaprofenic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Tiaprofenic acid.Investigational
TiboloneTiaprofenic acid may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTiaprofenic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tiaprofenic acid.Investigational
TioclomarolTiaprofenic acid may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tixocortol.Approved, Withdrawn
TobramycinTiaprofenic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tiaprofenic acid.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTiaprofenic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Tiaprofenic acid.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tiaprofenic acid.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Trolamine salicylate.Approved
TrovafloxacinTiaprofenic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTiaprofenic acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tiaprofenic acid.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tiaprofenic acid.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.Approved, Investigational
VancomycinTiaprofenic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Tiaprofenic acid.Approved
VerteporfinTiaprofenic acid may increase the photosensitizing activities of Verteporfin.Approved, Investigational
WarfarinTiaprofenic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTiaprofenic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tiaprofenic acid.Approved, Investigational
ZeranolTiaprofenic acid may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tiaprofenic acid.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Tiaprofenic acid.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tiaprofenic acid.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015538
PubChem Compound
5468
PubChem Substance
46504590
ChemSpider
5269
BindingDB
223313
ChEBI
32221
ChEMBL
CHEMBL365795
Therapeutic Targets Database
DAP000973
PharmGKB
PA164764503
Wikipedia
Tiaprofenic_acid
ATC Codes
M01AE11 — Tiaprofenic acid
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Capsule, extended releaseOral300 mg
TabletOral200 mg
TabletOral300 mg
Prices
Unit descriptionCostUnit
Apo-Tiaprofenic 300 mg Tablet0.43USD tablet
Novo-Tiaprofenic 300 mg Tablet0.43USD tablet
Nu-Tiaprofenic 300 mg Tablet0.43USD tablet
Apo-Tiaprofenic 200 mg Tablet0.36USD tablet
Novo-Tiaprofenic 200 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)96 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP3.22ALOGPS
logP3.66ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.03ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.19 m3·mol-1ChemAxon
Polarizability26.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a5i-3910000000-04c8e1561815c7f17b73

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Thiophene carboxylic acids and derivatives / Benzoyl derivatives / 2,5-disubstituted thiophenes / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Aryl-phenylketone / Thiophene carboxylic acid or derivatives / Benzoyl / 2,5-disubstituted thiophene / Benzenoid / Monocyclic benzene moiety / Heteroaromatic compound / Thiophene / Organoheterocyclic compound / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, thiophenes, aromatic ketone (CHEBI:32221)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. [PubMed:2277128]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [PubMed:14592549]
  2. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [PubMed:14741265]
  3. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823]
  4. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [PubMed:15575422]

Drug created on August 29, 2007 12:44 / Updated on August 14, 2018 04:32